The scientists from Tianjin University first cultivated brain-like organoids for a period of 90 days and then secured them onto a 3D-printed scaffold, where the tissue was wired to dual-grip flexible ...

DURHAM, N.C., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at ...

Impaired blood circulation in the lower limbs is a common health problem among the elderly and one of the most prominent ...

Bioprinting is an additive manufacturing process, wherein successive layers of cell-laden bioinks are used to form biological ...

Impaired blood circulation in the lower limbs is a common health problem among the elderly and one of the most prominent ...

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery ...

Humacyte ( (HUMA) ) has released its Q3 earnings. Here is a breakdown of the information Humacyte presented to its investors. Humacyte, Inc., a ...

The Vascular Ehlers-Danlos Syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage ...

Mapping cell types in MS lesions reveals unique tissue niches and interactions, offering insights into the molecular drivers of multiple sclerosis progression.

ONVO READ THE FULL ONVO RESEARCH REPORT Organovo Holdings (NASDAQ:ONVO) is a biotechnology company that is both a developer of 3D tissue technology that has the potential to change the way treatments ...